|
|
Advanced CT imaging as good as angiography to detect CAD blockages. |
|
EurekAlert: "We found that the 320-detector CT scanner allowed us to see the anatomy of the blockages and determine whether the blockages were causing a lack of perfusion to the heart," sayslead author Carlos E. Rochitte, M.D., a cardiologist at the Heart Institute (InCor), University of Sao Paulo Medical School, in Brazil, "We were therefore able to correctly identify the patients who needed revascularization within 30 days of their evaluation."
|
|
|
Gene therapy shows long-lasting benefits in patients with heart failure. |
|
EurekAlert: The new long-term follow-up results from their initial Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID 1) clinical trial found a one-time, high-dose injection of the AAV1/SERCA2a gene therapy results in the presence of the delivered SERCA2a gene up to 31 months in the cardiac tissue of heart failure patients. In addition, study results show clinical event rates in gene therapy patients are significantly lower three years later compared to those patients receiving placebo. Also, patients experienced no negative side effects following gene therapy delivery at three-year follow-up.
|
|
Aldehyde compound stimulates UC-1 to burn body fat. |
|
Vienna U. of Veterinary Medicine: A research team at the University of Veterinary Medicine (Vetmeduni Vienna) has found that a specific chemical compound, an aldehyde, can activate UCP1 under certain conditions, and that could also trigger fat burning. The data were published in the Journal Plos One.
|
|
Low-dose dopamine or nesiritide of no help in acute heart failure. |
|
Mayo Clinic: In the Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF) randomized 26-site trial in the U.S. and Canada, researchers analyzed data on 360 hospitalized acute heart failure patients with kidney dysfunction from September 2010 to March 2013. Compared to placebo, researchers found that neither dopamine nor nesiritide, when also used with diuretic (water pills) therapy, was better at increasing urine volume or improving levels of serum cystatin-C, an indicator of kidney function, at the end of a 72-hour treatment.
|
|
Eveolocumab lowers LDL cholesterol in patients with marked hypercholesterolemia. |
|
Amgen: The 52-week open label study, showed that monthly treatment Evolocumab reduced cholesterol levels up to 52 percent in combination with SOC in patients with high cholesterol, and also prevented major increase in adverse events. Meanwhile, 81.4 percent of patients showed adverse events including nasopharyngitis, upper respiratory tract infections, influenza, arthralgia, and back pain. Other minor reported events include muscle-problems, elevated liver function, elevated creatine kinase.
|
|
|
|
|
<< Start < Prev 231 232 233 234 235 236 237 238 239 240 Next > End >>
|
|
Page 234 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
